



131 Reg for Rec.
4 transmision
PATENT 1116
AMENDMENT UNDER 37 CFR 1.116 - 1116
EXPEDITED PROCEDURE - GROUP 1502

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 1316

In re Application of)
Mitsuji Akazawa) Group: 1502
Serial No. 08/579,469)
Filed: December 27, 1995) Examiner: D. Phelan
Title: EXTERNAL ANTI-INFLAMMATORY)
AND ANALGESIC PLASTER)
PREPARATION)

AMENDMENT AFTER FINAL ACTION

BOX AF
Assistant Commissioner
for Patents
Washington, D.C. 20231

Sir:

This is responsive to the Office Action mailed May 20, 1996. In the Office Action the Examiner issued a final rejection of all pending claims, namely claims 5-8.

Claims 5, 6 and 8 were rejected under 35 U.S.C. Section 103 as being unpatentable over Assandri et al. (Drugs Exptl. Clin. Res.). Claim 7 was rejected over 35 U.S.C. Section 103 as being unpatentable over Assandri as applied to claims 5, 6 and 8 above, and further in view of Okuyama (EPO 0,524,582). Prior to responding to the substantive rejections, Applicant respectfully points out to the Examiner that the Office Action includes certain typographical errors with reference to the Section 103 rejection. Although it is stated in paragraph 3 of the Office Action that "Claim 8 is rejected under 35 U.S.C. Section 103 as being unpatentable over Assandri as applied to claims 5, 6 and 9 above, and further in view of Okuyama . . .," (emphasis added) it is believed that the actual rejection is that which has been recited above by Applicant. There is no claim 9 in the application.